AU2006345003A1 - Broad spectrum antibacterial compounds - Google Patents

Broad spectrum antibacterial compounds Download PDF

Info

Publication number
AU2006345003A1
AU2006345003A1 AU2006345003A AU2006345003A AU2006345003A1 AU 2006345003 A1 AU2006345003 A1 AU 2006345003A1 AU 2006345003 A AU2006345003 A AU 2006345003A AU 2006345003 A AU2006345003 A AU 2006345003A AU 2006345003 A1 AU2006345003 A1 AU 2006345003A1
Authority
AU
Australia
Prior art keywords
nsc
compound
indole
amidine
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006345003A
Other languages
English (en)
Inventor
Sina Bavari
Rick Gussio
Rekha G. Panchal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Army Medical Research and Development Command
Original Assignee
Us Gov Represented By Secretary Of United States Army And U S Army Medical Research & AS
US Army Medical Research and Development Command
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Represented By Secretary Of United States Army And U S Army Medical Research & AS, US Army Medical Research and Development Command filed Critical Us Gov Represented By Secretary Of United States Army And U S Army Medical Research & AS
Publication of AU2006345003A1 publication Critical patent/AU2006345003A1/en
Priority to AU2013202450A priority Critical patent/AU2013202450B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
AU2006345003A 2005-08-12 2006-08-11 Broad spectrum antibacterial compounds Abandoned AU2006345003A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013202450A AU2013202450B2 (en) 2005-08-12 2013-04-04 Broad spectrum antibacterial compounds

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US70753105P 2005-08-12 2005-08-12
US60/707,531 2005-08-12
US72344205P 2005-10-05 2005-10-05
US60/723,442 2005-10-05
PCT/US2006/031550 WO2008041966A2 (en) 2005-08-12 2006-08-11 Broad spectrum antibacterial compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013202450A Division AU2013202450B2 (en) 2005-08-12 2013-04-04 Broad spectrum antibacterial compounds

Publications (1)

Publication Number Publication Date
AU2006345003A1 true AU2006345003A1 (en) 2008-04-10

Family

ID=39268919

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006345003A Abandoned AU2006345003A1 (en) 2005-08-12 2006-08-11 Broad spectrum antibacterial compounds

Country Status (6)

Country Link
US (3) US7825154B2 (enExample)
EP (1) EP1945209B1 (enExample)
JP (1) JP5390186B2 (enExample)
AU (1) AU2006345003A1 (enExample)
CA (1) CA2617123C (enExample)
WO (1) WO2008041966A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7825154B2 (en) * 2005-08-12 2010-11-02 The United States Of America As Represented By The Secretary Of The Army Small molecule inhibitors of botulinum neurotoxins
CA2672290A1 (en) * 2007-01-15 2008-07-24 The United States Of America, As Represented By The Secretary Of The Arm Y, On Behalf Of The U.S. Army Research Institute Of Infectious Diseases Antiviral compounds and methods of using thereof
RU2010120686A (ru) * 2007-10-24 2011-11-27 Фанкшенл Дженетикс,Инк. (Us) Способы ингибирования вирусной инфекции
JP5795714B2 (ja) * 2008-01-15 2015-10-14 シガ・テクノロジーズ・インコーポレーテッド アレナウイルス感染症の治療のための抗ウイルス薬
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
WO2011022721A1 (en) * 2009-08-21 2011-02-24 Microbiotix, Inc Inhibitors of botulinum neurotoxins
US8569346B1 (en) 2009-10-14 2013-10-29 Biomadison, Inc. Thiazoline ring compounds as botulinum antagonists
US20110152343A1 (en) * 2009-12-22 2011-06-23 Functional Genetics, Inc. Protease inhibitors and broad-spectrum antiviral
CA2801274C (en) 2010-06-01 2021-06-15 Summit Corporation Plc Compounds for the treatment of clostridium difficile-associated disease
WO2011151618A2 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile-associated disease
WO2011151619A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
WO2011151620A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
WO2011151617A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
WO2012087833A1 (en) 2010-12-22 2012-06-28 Abbott Laboratories Hepatitis c inhibitors and uses thereof
JP6106603B2 (ja) * 2011-01-11 2017-04-05 スノビオン プハルマセウトイカルス インコーポレイテッド ヘテロアリール化合物及びその使用方法
WO2013052263A2 (en) * 2011-09-16 2013-04-11 Microbiotix, Inc. Antifungal compounds
WO2013040526A1 (en) * 2011-09-16 2013-03-21 Microbiotix, Inc. Antimicrobial compounds
US9079935B2 (en) 2012-08-13 2015-07-14 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Reducing risk of contracting Clostridium-difficile associated disease
BR112015004666B1 (pt) * 2012-09-07 2022-04-26 Novartis Ag Derivados de indol carboxamida, seu uso, e composição farmacêutica
US10724070B2 (en) * 2012-11-14 2020-07-28 University Of Cincinnati Modified bacterial pathogens and methods for effectuating rapid response to contamination by known or unknown bacterial pathogens
US20180000793A1 (en) 2015-02-06 2018-01-04 Ernesto Abel-Santos Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
CN105311020B (zh) * 2015-11-25 2017-12-15 临沂大学 一种双苯并咪唑胺类化合物及其制备方法
CN105287522B (zh) * 2015-11-25 2017-12-15 临沂大学 双苯并咪唑胺类化合物在制备抗微生物药物中的用途
US10526343B2 (en) 2018-03-26 2020-01-07 University Of Sharjah Heterocyclic systems and pharmaceutical applications thereof
WO2020097396A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
US12509455B2 (en) 2018-11-07 2025-12-30 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof
JP7730803B2 (ja) 2019-07-17 2025-08-28 サミット （オックスフォード） リミティド リジニラゾールの調製方法およびその結晶形態
CN114364259B (zh) * 2019-09-11 2025-03-21 帝斯曼知识产权资产管理有限公司 杀菌用途
JP7582751B2 (ja) * 2019-09-11 2024-11-13 ディーエスエム アイピー アセッツ ビー．ブイ． 局所用組成物
CA3156828A1 (en) 2019-10-03 2021-04-08 Dana-Farber Cancer Institute, Inc. Tricyclic kinase inhibitors and uses thereof
US20230054976A1 (en) * 2019-12-19 2023-02-23 The Scripps Research Institute METHODS FOR INHIBITION OF ALPHA-SYNUCLEIN mRNA USING SMALL MOLECULES
IL272003A (en) 2020-01-13 2021-07-29 The Israel Institute Of Biological Res Iibr Compounds for use in treatment and/or prevention of clostridial neurotoxins intoxication
TW202140477A (zh) 2020-02-12 2021-11-01 美商必治妥美雅史谷比公司 雜環ｐａｄ４抑制劑
TW202204350A (zh) 2020-05-06 2022-02-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
EP4267559A1 (en) * 2020-12-22 2023-11-01 Gilead Sciences, Inc. Substituted indole compounds
EP4267560A1 (en) * 2020-12-22 2023-11-01 Gilead Sciences, Inc. 6-substituted indole compounds
EP4267574B1 (en) 2020-12-23 2025-04-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
GB202100470D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Solid tablet dosage for of ridinilazole
GB202100471D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Preparation of antibacterial compounds
US11661431B2 (en) 2021-04-16 2023-05-30 Gilead Sciences, Inc. Thienopyrrole compounds
US12220421B2 (en) 2021-09-09 2025-02-11 The Boards Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Inhibitors of C. difficile spore germination
TW202440078A (zh) 2021-09-10 2024-10-16 美商基利科學股份有限公司 噻吩并吡咯化合物
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2195850A1 (en) * 1994-08-03 1996-02-15 Asta Medica Aktiengesellschaft Substituted indoles
FR2819407B1 (fr) * 2001-01-18 2003-02-21 Oreal Compositions antisolaires a base d'un extrait d'au moins une bacterie filamenteuse non photosynthetique et d'au moins un flitre organique insoluble
EP1556035A4 (en) * 2002-09-20 2006-09-13 Genelabs Tech Inc NEW AROMATIC COMPOUNDS WITH ANTIMYCOTIC OR ANTIBACTERIAL EFFECT
EP1558341A4 (en) * 2002-11-01 2010-09-08 Paratek Pharm Innc TRANSCRIPTION FACTOR MODULATING CONNECTIONS AND THEIR USE
US7635685B2 (en) * 2003-07-03 2009-12-22 Technion Research & Development Foundation Ltd. Bifunctional antibiotics for targeting rRNA and resistance-causing enzymes and for inhibition of anthrax lethal factor
EP1663959A4 (en) 2003-09-05 2007-10-31 Univ North Carolina NEW AMIDINE COMPOUNDS FOR THE TREATMENT OF MICROBIAL INFECTIONS
US7574340B2 (en) * 2003-09-08 2009-08-11 The United States Of America As Represented By The Secretary Of The Army Small molecules and a pharmacophore model for inhibition of botulinum toxin and methods of making and using thereof
WO2005109304A2 (en) * 2003-12-24 2005-11-17 United States Army Medical Research And Materiel Command Small molecules and a pharmacophore model for inhibition of anthrax lethal factor
US7825154B2 (en) * 2005-08-12 2010-11-02 The United States Of America As Represented By The Secretary Of The Army Small molecule inhibitors of botulinum neurotoxins

Also Published As

Publication number Publication date
US20070112049A1 (en) 2007-05-17
US20110086877A1 (en) 2011-04-14
EP1945209A2 (en) 2008-07-23
US20070112048A1 (en) 2007-05-17
CA2617123C (en) 2015-05-26
CA2617123A1 (en) 2007-02-12
WO2008041966A3 (en) 2008-12-11
JP5390186B2 (ja) 2014-01-15
WO2008041966A2 (en) 2008-04-10
US7825154B2 (en) 2010-11-02
US8691859B2 (en) 2014-04-08
EP1945209A4 (en) 2012-07-25
EP1945209B1 (en) 2018-05-30
JP2009507932A (ja) 2009-02-26

Similar Documents

Publication Publication Date Title
EP1945209B1 (en) Broad spectrum antibacterial compounds
AU2017201670B2 (en) A composition comprising an antibiotic and a dispersant or an anti-adhesive agent
RU2478385C2 (ru) Соединения триазола для лечения образования биопленок
US20230330065A1 (en) RelA Inhibitors for Biofilm Disruption
WO2008049856A2 (en) Methods of treating pain using cdk inhibitors
CA2672290A1 (en) Antiviral compounds and methods of using thereof
AU2013202450B2 (en) Broad spectrum antibacterial compounds
EP3639855A1 (en) Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent
WO2010056914A1 (en) Bacterial helicase inhibitor compounds and uses thereof
JP2017538675A (ja) 微生物感染を治療するための相乗的組成物
CN102464603B (zh) 吲哚满二酮衍生物及其在制备抗超级耐药菌药物中的用途
JP6478378B2 (ja) 抗菌剤
US11617741B1 (en) Method for inhibiting growth of bacteria
CA2497410A1 (en) Antibacterial pyrazole carboxylic acid hydrazides
TW200427458A (en) Crystalline N-formyl hydroxylamine compounds
RU2400471C1 (ru) N-замещенные производные тиогидразидов оксаминовых кислот, способ их получения и их использование
RU2495036C1 (ru) Биологически активные вещества, подавляющие патогенные бактерии, и способ ингибирования секреции iii типа у патогенных бактерий
CA2909383A1 (en) Phthalocyanine compounds useful as reca inhibitors and methods of using same
HK40074155A (en) Antibacterial compounds
US20160000079A1 (en) Novel small molecule inhibitors of biofilm formation and the novel use of previously identified compounds for inhibition of biofilm formation and applications for drug therapy and medical device coating

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted